Clinical Trial Update: Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating an ADA gene therapy vector delivered via peripheral blood for Adenosine Deaminase Severe Combined Immunodeficiency, sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosine Deaminase Severe Combined Immunodeficiency

Drugs mentioned

• EFS ADA Vector (ADA gene therapy vector)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Adenosine Deaminase Severe Combined Immune Deficiency | Phase 1, Phase 2 | Status: RECRUITING